Navigation Links
IDEV Announces Full Canadian Regulatory Approval for SUPERA VERITAS®
Date:4/14/2011

WEBSTER, Texas, April 14, 2011 /PRNewswire/ -- The Medical Devices Bureau of Health Canada has granted regulatory approval for the SUPERA VERITAS stent system for use in biliary and peripheral procedures.  IDEV's unique stent was previously available on a limited basis only, through the Special Access Program.

Christopher Owens, President and CEO of IDEV, commented, "With the full regulatory approval that has been granted we can immediately launch SUPERA VERITAS throughout Canada.  Based on early work with key physicians we anticipate rapid acceptance of our technology, and are pleased to offer this treatment option to physicians and their patients."

The approval clears the way for clinicians to utilize the SUPERA stent for patients with peripheral vascular disease (PVD) as well as those diagnosed with biliary strictures resulting from malignant neoplasms.  The proven mechanical characteristics of the SUPERA stent, including unmatched radial strength and fracture resistance, may result in improved clinical outcomes for these patients.

"Gaining full approval in Canada for SUPERA VERITAS is a significant development for the market," stated Vincent Oliva, M.D., Chief of Interventional Radiology at Centre Hospitalier de L'Universite de Montreal (CHUM).  "Based upon my experience, the highly differentiated features of the device, including its high radial strength and fracture resistance, and the clinical data presented showing exceptional outcomes, provide clinicians with a new and exciting option for treating PVD."

About IDEV Technologies, IncorporatedIDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology.  IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.  For more information please visit www.idevmd.com.

The SUPERA stent is currently indicated in the U.S. for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe and Australia for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).Contact:

Donna LucchesiVice President Global MarketingIDEV Technologies, Incorporated(281) 525-2000
'/>"/>

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)... , Aug. 2, 2017 CaryRx, a next-generation full-service ... delivery service for patients in the Washington D.C. ... retail pharmacy by providing delivery of medications through the convenience ... future delivery or delivered within one hour to any location ... excited to bring this invaluable service to Washington ...
Breaking Medicine Technology:
(Date:8/18/2017)... CA & CARMEL, IN (PRWEB) , ... August 18, 2017 , ... ... on its 36th annual list, the most prestigious ranking of the nation's fastest-growing private ... been included in the exclusive Inc. 5000 ranking . This year’s ranking reflects ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Three Narrow Roads”: a vivid and ... of published author, Rev. Dr. Burnett King Sr., is currently the pastor-teacher-visionary at Simply ... the Faith Track Club, Inc., a track-and-field program geared towards youth. , King shares, ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Kingdom Mandate for Kingdom Builders”: ... “Kingdom Mandate for Kingdom Builders” is the creation of published author, John F. ... Eastern Europe as a missionary in 1983. He spent three decades training pastors ...
(Date:8/17/2017)... ... August 17, 2017 , ... Riccobene Associates ... location in Goldsboro, NC to its family of practices. Residents of Goldsboro will ... starting August 15, 2017. , Riccobene Associates Family Dentistry, founded by Dr. ...
(Date:8/17/2017)... MA (PRWEB) , ... August 17, 2017 , ... ... will come together on September 19, 2017 for Anti-Infectives Rx. This off-the-record networking ... B. Martin Conference Center at Harvard Medical School. , Industry leaders and decision ...
Breaking Medicine News(10 mins):